Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Azathioprine
Drug ID BADD_D00195
Description Azathioprine is a prodrug of 6-mercaptopurine, first synthesized in 1956 by Gertrude Elion, William Lange, and George Hitchings in an attempt to produce a derivative of 6-mercaptopurine with a better therapeutic index.[A189678,A189687,A189690] Azathioprine is used to treat inflammatory conditions like rheumatoid arthritis and as an immunosuppressant in the prevention of renal transplant rejection.[L11214] Azathiprine was granted FDA approval on 20 March 1968.[L11214]
Indications and Usage Azathioprine is indicated to treat rheumatoid arthritis and prevent renal transplant rejection.[L11214]
Marketing Status approved
ATC Code L04AX01
DrugBank ID DB00993
KEGG ID D00238
MeSH ID D001379
PubChem ID 2265
TTD Drug ID D07QCE
NDC Product Code 62991-2189; 65649-231; 67877-492; 68084-229; 68382-120; 51407-182; 68382-118; 72789-129; 46014-1110; 70771-1141; 60219-1076; 60219-2036; 60219-2037; 68382-003; 48954-909; 51927-0071; 68682-241; 70518-3544; 70771-1140; 51927-2258; 54766-590; 65841-602; 12780-0300; 38779-0312; 66122-0009; 42291-063; 68462-502; 71610-124; 42291-071; 68682-231; 70771-1139; 15308-0732; 49452-0783; 67877-493; 51552-0779; 65649-241; 67877-494; 67877-495; 68382-119; 42973-143
UNII MRK240IY2L
Synonyms Azathioprine | Azothioprine | Imurel | Imuran | Immuran | Azathioprine Sodium | Sodium, Azathioprine | Azathioprine Sodium Salt | Azathioprine Sulfate
Chemical Information
Molecular Formula C9H7N7O2S
CAS Registry Number 446-86-6
SMILES CN1C=NC(=C1SC2=NC=NC3=C2NC=N3)[N+](=O)[O-]
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Colon cancer16.13.01.001; 07.21.01.0010.000470%Not Available
Condition aggravated08.01.03.0040.010559%Not Available
Conjunctivitis allergic10.01.04.002; 06.04.01.0030.000313%Not Available
Constipation07.02.02.001--
Conversion disorder19.24.01.0010.000313%Not Available
Cough22.02.03.001--
Crohn's disease10.02.01.005; 07.08.01.0150.033618%Not Available
Crying17.02.05.013; 12.02.11.001; 08.01.03.005; 19.04.02.0020.000470%Not Available
Cushing's syndrome24.08.04.001; 19.07.03.002; 14.11.01.007; 05.01.01.0010.000313%Not Available
Cutaneous vasculitis24.12.04.008; 23.06.02.001; 10.02.02.0030.000627%Not Available
Cyst16.02.02.002; 08.03.05.0010.000783%Not Available
Deafness neurosensory17.04.07.001; 04.02.01.0020.000313%Not Available
Defaecation urgency07.02.04.0010.001159%Not Available
Dehydration14.05.05.001--
Demyelination17.16.02.0010.000940%Not Available
Dental caries07.09.01.0010.000313%
Depressed mood19.15.02.001--Not Available
Dermal cyst23.10.02.001; 16.26.02.0010.000313%Not Available
Dermatitis23.03.04.0020.001316%Not Available
Dermatitis allergic10.01.03.014; 23.03.04.0030.000313%Not Available
Dermatomyositis15.05.01.002; 10.04.04.027; 23.03.02.0010.000313%Not Available
Diarrhoea07.02.01.001--
Diarrhoea haemorrhagic24.07.02.004; 07.02.01.0020.002882%Not Available
Diffuse large B-cell lymphoma16.28.02.001; 01.15.02.0010.001723%Not Available
Discomfort08.01.08.003--Not Available
Disseminated intravascular coagulation24.01.01.010; 01.01.02.0020.000470%
Diverticulitis11.01.07.003; 07.10.02.001--Not Available
Diverticulum07.10.01.001--Not Available
Dizziness24.06.02.007; 17.02.05.003; 02.11.04.006--
Drug eruption23.03.05.001; 10.01.01.005; 08.01.06.0150.000470%Not Available
The 4th Page    First    Pre   4 5 6 7 8    Next   Last    Total 25 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene